"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT03696628","Modeling and Pharmacological Targeting of Genetic Cardiomyopathy in Children Via Cardiomyocytes Derived From Induced Pluripotent Stem Cells (DMDstem)","DMDstem","Recruiting","No Results Available","Cardiomyopathy, Familial","Other: Electrocardiogram|Other: physical examination|Other: echocardiography|Biological: blood test","hiPSC-cardiomyocytes culture","University Hospital, Montpellier","All","up to 17 Years   (Child)","Not Applicable","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","9806|2017-A01589-44","September 25, 2017","April 2021","April 2022","October 4, 2018",,"December 3, 2020","CHU Arnaud de Villeneuve, Montpellier, Occitanie, France",,"https://ClinicalTrials.gov/show/NCT03696628"
2,"NCT04696328","Clinical Trial of Human (Allogeneic) iPS Cell-derived Cardiomyocytes Sheet for Ischemic Cardiomyopathy",,"Recruiting","No Results Available","Myocardial Ischemia","Biological: Human (allogeneic) iPS cell derived-cardiomyocyte sheet","The number of patients with improved LVEF|Incidence of adverse events and defects [Safety and Tolerability]|Incidence of serious adverse events [Safety and Tolerability]|Incidence of abnormal vital signs [Safety and Tolerability]|Incidence of abnormal general blood tests [Safety and Tolerability]|Incidence of abnormal blood biochemical tests [Safety and Tolerability]|Incidence of abnormal tumor marker tests [Safety and Tolerability]|Incidence of cardiac function clinical events such as death and hospitalization [Safety and Tolerability]|Number of Responder patients 26 and 52 weeks after transplantation of this product|Contraction function of the entire left ventricle|Left ventricular remodeling (LVESVI)|Left ventricular remodeling (LVEDVI)|New York Heart Association functional classification|Specific Activity Scale (SAS)|The Minnesota Living with Heart Failure Questionnaire|36-Item Short Form Survey (SF-36)|6-minute walking distance|Brain natriuretic peptide (BNP)|N-terminal pro-brain natriuretic peptide (NT-proBNP)|Exercise tolerance (VO2max)|Exercise tolerance (AT)|Exercise tolerance (VE/VCO2)|Cumulative number of rejections that occurred during the observation period","Osaka University|Cuorips Inc.","All","20 Years and older   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CVSC0005","December 2, 2019","May 30, 2022","May 30, 2023","January 6, 2021",,"April 20, 2021","Osaka University Hospital, Suita, Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT04696328"
3,"NCT04097275","Induced Pluripotent Stem Cells for the Development of Novel Drug Therapies for Inborn Errors of Metabolism (iPSC-IEM)","iPSC-IEM","Recruiting","No Results Available","Inborn Errors of Metabolism","Other: Skin biopsy|Other: Withdraw of blood","Generation of patient-specific induced pluripotent stem cells and then differentiate them into neural cells.","CENTOGENE GmbH Rostock","All","2 Months to 50 Years   (Child, Adult)",,"1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","iPSC-IEM-2019","August 1, 2019","August 1, 2021","August 1, 2024","September 20, 2019",,"May 17, 2021","Children Hospital and Institute of Child Health, Lahore, Pakistan",,"https://ClinicalTrials.gov/show/NCT04097275"
4,"NCT04476225","Induced Pluripotent Stem Cells for Disease Research",,"Recruiting","No Results Available","Hirschsprung Disease",,"Whole blood sample collection|iPSC disease modeling","University of California, San Francisco","All","13 Years to 100 Years   (Child, Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","19-27665","September 30, 2021","March 2023","March 2023","July 20, 2020",,"July 21, 2021","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04476225"
5,"NCT03883750","Induced Pluripotent Stem Cells for Niemann Pick Disease","IPSNPABC","Completed","No Results Available","Niemann-Pick Diseases",,"To generate patient-specific induced pluripotent stem cells and then differentiate them into neural cells","CENTOGENE GmbH Rostock","All","6 Months to 80 Years   (Child, Adult, Older Adult)",,"40","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IPSNPABC 6-2018","June 19, 2018","December 1, 2019","December 1, 2019","March 21, 2019",,"April 9, 2021","Childrens Hospital and Institute of Child Health, Ferozepur Road, Lahore, Pakistan",,"https://ClinicalTrials.gov/show/NCT03883750"
6,"NCT02720939","ASD-specific Induced Pluripotent Stem Cells for Disease Modeling",,"Completed","No Results Available","Autism Spectrum Disorder",,"iPSC derivation and characterization","National Taiwan University Hospital","All","Child, Adult, Older Adult",,"20","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","201507086RINA","January 1, 2016","December 31, 2016","December 31, 2016","March 28, 2016",,"September 2, 2021","National Taiwan Univeristy Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02720939"
7,"NCT03971812","Organoids Derived From Induced-Pluripotent Stem Cells (iPS) From Patients With High Grade Astrocytoma","GLIOMANOID","Unknown status","No Results Available","Glioma","Biological: Blood sample","Characterize the level of proliferation of organoids","Assistance Publique Hopitaux De Marseille","All","18 Years and older   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Other|Time Perspective: Prospective","2019-01|2019-A00145-52|RCAPHM19_0001","June 7, 2019","December 6, 2020","December 6, 2020","June 3, 2019",,"June 13, 2019","Assistance Publique Hôpitaux de Marseille, Marseille, France",,"https://ClinicalTrials.gov/show/NCT03971812"
8,"NCT01517425","Evaluating Cardiovascular Phenotypes Using Induced Pluripotent Stem Cells","iPSC","Enrolling by invitation","No Results Available","Coronary Artery Disease",,"iPSC development","Scripps Translational Science Institute","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","11-5676","November 2012","July 2025","July 2030","January 25, 2012",,"March 17, 2021","Scripps Translational Science Institute, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT01517425"
9,"NCT03612310","Developing Protocols for Modelling of Genetic Diseases Using Induced Pluripotent Stem Cells",,"Not yet recruiting","No Results Available","Genetic Disease","Procedure: Skin biopsy/Urine Collection/Blood Sample Collection","Number of disease relevant iPSC differentiation protocols generated within the study","Kevin Bruce|Censo Biotechnologies Ltd","All","1 Year to 120 Years   (Child, Adult, Older Adult)",,"3000","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","18/SS/0061","November 1, 2018","July 1, 2020","July 1, 2028","August 2, 2018",,"August 2, 2018",,,"https://ClinicalTrials.gov/show/NCT03612310"
10,"NCT02815072","Generation of Marfan Syndrome and Fontan Cardiovascular Models Using Patient-specific Induced Pluripotent Stem Cells",,"Unknown status","No Results Available","Marfan's Syndrome","Other: Skin biopsy","Generation of Marfan Syndrome and Fontan Cardiovascular Models using Patient-specific Induced Pluripotent Stem Cells","National Heart Centre Singapore","All","21 Years to 60 Years   (Adult)",,"30","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2013/596/C","October 2013","May 2017","May 2017","June 28, 2016",,"June 28, 2016","National Heart Centre Singapore, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT02815072"
11,"NCT04339764","Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration",,"Recruiting","No Results Available","Age-Related Macular Degeneration","Device: iPSC-derived RPE/PLGA transplantation|Biological: Atuologous iPSC-derived RPE on PGLA","Visual acuity change|Summary of adverse events|Retinal Structure (optical coherence tomography)|Retinal sensitivity and fixation (microperimetry)|Multifocal electroretinography responses|Retinal Structure (color and autofluorescence imaging)|Retinal structure (fluorescein angiography)","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","55 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","200052|20-EI-0052","September 23, 2020","May 31, 2029","May 31, 2029","April 9, 2020",,"September 22, 2021","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04339764"
12,"NCT04396899","Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure","BioVAT-HF","Recruiting","No Results Available","Heart Failure","Biological: EHM implantation","Target heart wall thickness|Heart wall thickening fraction","University Medical Center Goettingen|Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)|University Medical Center Freiburg","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","53","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","02289","February 3, 2020","March 2024","October 2024","May 21, 2020",,"February 21, 2021","University Medical Center Göttingen, Göttingen, Lower Saxony, Germany|Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, North Rhine-Westphalia, Germany|University Medical Center Schleswig-Holstein, Lübeck, Schleswig-Holstein, Germany",,"https://ClinicalTrials.gov/show/NCT04396899"
13,"NCT00801333","Derivation of Induced Pluripotent Stem Cells From an Existing Collection of Human Somatic Cells",,"Recruiting","No Results Available","Amyotrophic Lateral Sclerosis",,,"Hadassah Medical Organization","All","18 Years and older   (Adult, Older Adult)",,"25","Other","Observational","Observational Model: Other|Time Perspective: Prospective","0511-08-HMO","November 2008","December 2025","December 2025","December 3, 2008",,"August 12, 2021","Hadassah Medical Organization - Ein Kerem Campus, Jerusalem, Israel|Hadassah Ein Kerem, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT00801333"
14,"NCT03407040","Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy",,"Terminated","No Results Available","Gastrointestinal Cancers|Breast Cancer|Pancreatic Cancer|Melanoma|Lung Cancer",,"Production of cancer antigen-specific T-cells|Availability of stored specimens and/or data","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","All","15 Years and older   (Child, Adult, Older Adult)",,"98","NIH","Observational","Observational Model: Cohort|Time Perspective: Retrospective","180043|18-C-0043","January 30, 2018","August 27, 2019","September 30, 2019","January 23, 2018",,"November 10, 2021","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03407040"
15,"NCT00801372","Use of Existing Fibroblast Cells to Convert to Induced Pluripotent Stem Cells",,"Recruiting","No Results Available","Pregnant, Healthy Females|Healthy Male Newborns",,,"Hadassah Medical Organization","All","18 Years and older   (Adult, Older Adult)",,"1","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","0522-08- HMO-CTIL","November 2008","December 2025","December 2025","December 3, 2008",,"August 12, 2021","Hadassah Ein Kerem, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT00801372"
16,"NCT02056613","Blood Collection From Healthy Volunteers and Patients for the Production of Clinical Grade Induced Pluripotent Stem Cell (iPSC) Products",,"Withdrawn","No Results Available","Induced Pluripotent Stem Cells",,"collection of blood samples for production of iPSCs or iPSV-derived therapy products","National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"0","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","140057|14-CC-0057","February 5, 2014","November 1, 2018","November 1, 2018","February 6, 2014",,"November 5, 2018",,,"https://ClinicalTrials.gov/show/NCT02056613"
17,"NCT01734356","Molecular Mechanism Identification in Inherited Arrhythmias and Valvulopathies From Induced Pluripotent Stem Cells","Diag-iPS","Terminated","No Results Available","Inherited Arrhythmias and Valvulopathies","Other: Skin biopsies","Production of cardiomyocytes modele from skin fibroblast of arrhythmic patient|Production of valve interstitial cells modele from skin fibroblast of patient with a valvulopathy","Nantes University Hospital","All","22 Years to 60 Years   (Adult)","Not Applicable","20","Other","Interventional","Masking: None (Open Label)","BRD/10/11-P","November 2011","November 2014","November 2014","November 27, 2012",,"November 7, 2014","Nantes University Hospital, Nantes, France",,"https://ClinicalTrials.gov/show/NCT01734356"
18,"NCT02246491","Cell-Based Approaches For Modeling and Treating Ataxia-Telangiectasia",,"Terminated","No Results Available","Ataxia-Telangiectasia (A-T)","Other: A-T iPS cell line|Other: Carrier patients iPS cell line","Number of samples of primary A-T fibroblast samples that can be successfully reprogrammed to iPSCs|Number of samples of patient A-T fibroblasts that can be reprogrammed to iPSCs with and without gene correction|Quantification of the cloning efficiency of primary cells haploinsufficient for ATM relative to healthy controls","Johns Hopkins University","All","3 Years to 100 Years   (Child, Adult, Older Adult)","Not Applicable","6","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IRB00038916|J1491","February 3, 2015","July 5, 2018","July 5, 2018","September 22, 2014",,"March 19, 2019","SKCCC at Johns Hopkins, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02246491"
19,"NCT01534624","Stem Cell Study of Genetics and Drug Addiction",,"Completed","No Results Available","Induced Pluripotent Stem Cells",,"Derive and characterize patient-specific, induced pluripotent stem (iPS) cells that carry monoamine transporter polymorphisms and differentiate them into dopaminergic neurons.","National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC)","All","21 Years to 65 Years   (Adult, Older Adult)",,"49","NIH","Observational","Time Perspective: Prospective","999912476|12-DA-N476","February 7, 2012",,"July 30, 2014","February 16, 2012",,"December 17, 2019","National Institute on Drug Abuse, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01534624"
20,"NCT03222453","Thalassemia Treatment Based on the Stem Cell Technology",,"Unknown status","No Results Available","Beta-Thalassemia","Biological: Hematopoetic stem cells","The check of granulocyte transplantation-granulocyte plant living standards|The check of granulocyte transplantation-platelet plant living standards|Effect of cell transplantation","Xiaofang Sun|Nanfang Hospital of Southern Medical University|Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences|Third Affiliated Hospital, Sun Yat-Sen University|The Third Affiliated Hospital of Guangzhou Medical University","Male","1 Year to 18 Years   (Child, Adult)","Not Applicable","2","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","201508020258","January 1, 2015","June 14, 2016","December 31, 2017","July 19, 2017",,"July 19, 2017",,,"https://ClinicalTrials.gov/show/NCT03222453"
21,"NCT03853252","iPS Cells of Patients for Models of Retinal Dystrophies","RETIPS","Recruiting","No Results Available","Retinal Dystrophies","Other: Skin biopsy","number of human cell models obtained","University Hospital, Montpellier|Institut National de la Santé Et de la Recherche Médicale, France","All","5 Years to 70 Years   (Child, Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","9366","November 3, 2014","November 2024","November 2024","February 25, 2019",,"March 31, 2020","CNMR Maolya, Genetic Sensory Diseases, Montpellier, Occitanie, France",,"https://ClinicalTrials.gov/show/NCT03853252"
22,"NCT01860898","A Phase I Study of iPS Cell Generation From Patients With COPD",,"Active, not recruiting","No Results Available","Thoracic Diseases|Respiratory Tract Diseases|Cancer of Lung|Cancer of the Lung|Lung Cancer|Lung Diseases, Obstructive|COPD|Pulmonary Emphysema|Neoplasms, Lung|Neoplasms, Pulmonary|Pulmonary Cancer|Pulmonary Neoplasms|Carcinoma, Non-Small-Cell Lung|Carcinoma, Small Cell","Other: Skin Biopsy","Feasibility","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Not Applicable","31","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","09-005334","September 2009","September 2023","September 2023","May 23, 2013",,"September 17, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01860898"
23,"NCT02417311","Individualized Early Risk Assessment for Heart Diseases","IndivuHeart","Unknown status","No Results Available","Cardiomyopathy, Hypertrophic|Cardiomyopathy, Dilated","Other: Skin biopsy, genotyping and disease phenotyping","generation of hiPSC-EHT and in vitro phenotyping|clinical phenotyping and disease progression|genotyping","Universitätsklinikum Hamburg-Eppendorf","All","18 Years to 60 Years   (Adult)",,"80","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","0174/134/2-1","June 2014","June 2019","June 2019","April 15, 2015",,"April 29, 2019","Department of Experimental Pharmacology and Toxicology, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT02417311"
24,"NCT02193724","Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma",,"Completed","No Results Available","Retinoblastoma","Other: Skin Biopsy|Other: Blood Draw","Number of samples which successfully produced iPSCs|Number of samples with validated RB1-deficient iPSCs|Number of samples that differentiate human iPSCs toward an eye field fate","St. Jude Children's Research Hospital|University of Wisconsin, Madison","All","Child, Adult, Older Adult",,"15","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RETCELL","November 4, 2014","August 23, 2019","August 23, 2019","July 18, 2014",,"October 23, 2020","St. Jude Children's Research Hospital, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02193724"
25,"NCT04945018","A Study of iPS Cell-derived Cardiomyocyte Spheroids (HS-001) in Patients With Heart Failure (LAPiS Study)","LAPiS","Not yet recruiting","No Results Available","Heart Failure|Ischemic Heart Disease","Biological: HS-001 CS|Device: HS-001-D needle, HS-001-D Adaptor","Safety and Tolerability|Left Ventricular Ejection Fraction in Cardiac MRI scan & Echocardiography|Myocardial wall motion evaluation in Echocardiography|Myocardial blood flow in SPECT|Myocardial viability in SPECT|6-minute walk distance|Kansas City Cardiomyopathy Questionnaire (KCCQ)|5-level EQ-5D version (EQ-5D-5L)|N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)","Heartseed Inc.","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HS-001-01","August 19, 2021","September 30, 2023","March 31, 2024","June 30, 2021",,"July 2, 2021","St. Marianna University Hospital, Kawasaki, Japan|Nihon University Itabashi Hospital, Tokyo, Japan|The University of Tokyo Hospital, Tokyo, Japan|Tokyo Medical and Dental University Medical Hospital, Tokyo, Japan|Tokyo Metropolitan Geriatric Medical Center, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT04945018"
26,"NCT02836145","Biomolecular Messages Associated With the Differentiation of Human Induced Pluripotent Stem Cells to Skeletal Muscle Progenitor Cells",,"Unknown status","No Results Available","Female Urinary Incontinence and Pelvic Organ Prolapse","Other: Differentiation of hiPSCs to skeletal muscle progenitors","Cell count","National Taiwan University Hospital","Female","20 Years to 80 Years   (Adult, Older Adult)",,"6","Other","Observational","Time Perspective: Prospective","NTU-REC-201603059RINA","August 2016","July 2017",,"July 18, 2016",,"July 18, 2016",,,"https://ClinicalTrials.gov/show/NCT02836145"
27,"NCT02162953","Stem Cell Models of Best Disease and Other Retinal Degenerative Diseases.",,"Active, not recruiting","No Results Available","Retinal Disease|Bestrophinopathy|Best Vitelliform Macular Dystrophy|Adult Onset Vitelliform Macular Dystrophy|Autosomal Dominant Vitreoretinalchoroidopathy",,"Number of iPS cells successfully differentiated into RPE cells","Mayo Clinic","All","5 Years and older   (Child, Adult, Older Adult)",,"100","Other","Observational","Observational Model: Other|Time Perspective: Prospective","13-008089","February 2014","December 2021","December 2021","June 13, 2014",,"February 23, 2021","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02162953"
28,"NCT03867526","Establishment of Human Cellular Disease Models for Wilson Disease","IPSWILSON","Completed","No Results Available","Wilson Disease",,"Reprogramming patient-derived fibroblasts into induced pluripotent stem cells (iPSCs)|Differentiation of patient-specific iPSCs into disease-affected cell types","CENTOGENE GmbH Rostock","All","6 Months to 80 Years   (Child, Adult, Older Adult)",,"40","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IPSWilson 06-2018","June 19, 2018","December 1, 2019","December 1, 2019","March 8, 2019",,"April 9, 2021","Childrens Hospital and Institute of Child Health, Ferozepur Road, Lahore, Pakistan",,"https://ClinicalTrials.gov/show/NCT03867526"
29,"NCT03872713","Establishment of Human Cellular Disease Models for Morquio Disease","IPSMORQUIO","Completed","No Results Available","Morquio Disease",,"Reprogramming patient-derived fibroblasts into induced pluripotent stem cells","CENTOGENE GmbH Rostock","All","12 Months and older   (Child, Adult, Older Adult)",,"40","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IPSM 09-2018","October 26, 2018","December 1, 2019","December 1, 2019","March 13, 2019",,"April 9, 2021","Childrens Hospital and Institute of Child Health, Ferozepur Road, Lahore, Pakistan",,"https://ClinicalTrials.gov/show/NCT03872713"
30,"NCT02772367","Generation of Heart Muscle Cells From Blood or Skin Cells of Breast Cancer Patients",,"Recruiting","No Results Available","Breast Cancer","Procedure: skin punch biopsy","derive iPSs from skin fibroblasts","Memorial Sloan Kettering Cancer Center|Icahn School of Medicine at Mount Sinai","Female","18 Years and older   (Adult, Older Adult)",,"70","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","16-025","May 2016","May 2022","May 2022","May 13, 2016",,"June 2, 2021","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02772367"
31,"NCT02464956","Production of iPSC Derived RPE Cells for Transplantation in AMD",,"Unknown status","No Results Available","Age Related Macular Degeneration (AMD)",,"Successful production of a Retinal Epithelial (RPE) layer that fulfils Regulatory Regulation for transplantation. This will be confirmed with standard laboratory characterisation of RPE and completed toxicity and safety studies on the cell layer.","Moorfields Eye Hospital NHS Foundation Trust|Medical Research Council","All","50 Years and older   (Adult, Older Adult)",,"10","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DACL1011","July 2015","April 2016","April 2016","June 8, 2015",,"June 8, 2015",,,"https://ClinicalTrials.gov/show/NCT02464956"
32,"NCT00874783","Development of iPS From Donated Somatic Cells of Patients With Neurological Diseases",,"Recruiting","No Results Available","Neurodegenerative Disorders",,,"Hadassah Medical Organization","All","18 Years and older   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","0599-08-HMO-CTIL","April 2009","December 2025","December 2025","April 3, 2009",,"August 12, 2021","Hadassah Ein Kerem, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT00874783"
33,"NCT03754088","In Vitro Model of the Cystic Fibrosis Bronchial Epithelium Via iPS Technology","PaCyFIC","Completed","No Results Available","Cystic Fibrosis",,"Obtention of induced pluripotent stem cell line (iPS): yes/no|Functional bronchial epithelium present for the iPS? yes/no|Cystic fibrosis transmembrane conductance regulator (CFTR) channel function: yes/no","University Hospital, Montpellier","All","18 Years and older   (Adult, Older Adult)",,"6","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RECHMPL17_0254|2017-A02341-52","February 14, 2019","April 25, 2019","April 25, 2019","November 27, 2018",,"June 17, 2019","Hôpital Arnaud de Villeneuve - CHU de Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT03754088"
34,"NCT01808729","CAUSE Trial: Patient Specific-Cellular Characterization of Fibromuscular Dysplasia and High-Risk Atherosclerotic Endothelium",,"Completed","No Results Available","Fibromuscular Dysplasia|Early Onset CAD",,"Phenotypic cellular differences (fibroblasts and/or ps-iPSC-ECs) between cases and controls","Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Older Adult)",,"34","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","GCO 11-1601|HS#: 11-02041","February 2013","October 2013","October 2013","March 11, 2013",,"November 5, 2013","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01808729"
35,"NCT03199300","Investigating Cardiovascular Adverse Events Related to Cancer Treatment","InvestiCAT","Recruiting","No Results Available","Toxicity Due to Chemotherapy|Cardiovascular Morbidity|Cancer, Treatment-Related","Drug: Anthracyclines|Drug: Trastuzumab|Drug: Cisplatin|Drug: Bleomycin","Comparison between iPSC-derived cells|Correlate the findings from the iPSC-derived cells with the clinical phenotype of cardiovascular toxicity","University Medical Center Groningen","All","18 Years and older   (Adult, Older Adult)",,"48","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","201700454","December 12, 2017","January 2022","January 2022","June 26, 2017",,"February 2, 2021","University Medical Center Groningen, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT03199300"
36,"NCT02980302","Development of the Tool "" iPSC "" for the Functional Study of Mutations Responsible for Mental Retardation","Rementips","Completed","No Results Available","Intellectual Deficiency|Asymptomatic Carrier of the Mutation of the Gene MYT1L|Healthy Volunteers","Procedure: Cutaneous biopsy","iPSC caracterization from human fibroblast with MYT1L mutation","University Hospital, Grenoble","All","Child, Adult, Older Adult","Not Applicable","4","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","38RC14.181","September 2015","June 2017","September 2017","December 2, 2016",,"October 12, 2018","UniversityHospitalGrenoble, La Tronche, France",,"https://ClinicalTrials.gov/show/NCT02980302"
37,"NCT03181204","Modeling Bronchial Epithelium Modifications Associated With COPD Using iPS","INVECCO","Recruiting","No Results Available","Pulmonary Disease, Chronic Obstructive|Smoking","Procedure: Bronchial biopsy|Procedure: Skin biopsy|Procedure: Blood sample","functional bronchial epithelium from iPS?|functional bronchial epithelium from HBEC-ALI?","University Hospital, Montpellier","All","18 Years to 55 Years   (Adult)",,"16","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","9791|2017-A00252-51","August 7, 2017","August 7, 2022","August 7, 2023","June 8, 2017",,"October 25, 2021","Centre Hospitalier Universitaire de Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT03181204"
38,"NCT01943383","Pharmacogenomic Evaluation of Antihypertensive Responses in Induced Pluripotent Stem (iPS) Cells Study","PEAR-iPSC","Completed","No Results Available","Hypertension","Genetic: iPSC","Cellular gene expression, cellular protein expression, and site directed mutagenesis of induced pluripotent stem cells in response to antihypertensive drugs.","University of Florida","All","18 Years to 75 Years   (Adult, Older Adult)",,"21","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","IRB201600901|093-2013","August 2013","May 2018","May 2018","September 17, 2013",,"May 31, 2018","University of Florida, Gainesville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01943383"
39,"NCT04122742","Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.","GENEPI","Recruiting","No Results Available","Rubinstein-Taybi Syndrome","Procedure: skin biopsy for the primary fibroblast culture and a 15 ml blood sample (3 unnamed samples of 5ml) in each of the 4 SRT patients included.|Other: Generation of Induced Pluripotent Stem Cells (iPSC) from fibroblasts obtained by skin biopsy|Other: Histone acetylation profiles of cells of SRT patients with CREBBP mutations|Other: Functional involvement of identified epigenetic alterations|Biological: Culture of lymphoblastoid line from blood sample","Identification of a specific acetylation profile of RSTS|Identification of different target genes between SRT patients and controls|Evidence of a significantly different level of expression for common target genes for RSTS patients and controls","University Hospital, Bordeaux","All","6 Years and older   (Child, Adult, Older Adult)",,"154","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CHUBX 2019/19","October 8, 2019","October 2022","October 2022","October 10, 2019",,"October 8, 2021","Centre Hospitalier Universitaire de Bordeaux, Talence, France",,"https://ClinicalTrials.gov/show/NCT04122742"
40,"NCT04537351","The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause","MEND","Recruiting","No Results Available","Covid19|Acute Respiratory Distress Syndrome","Biological: CYP-001","Trend in trajectory of PaO2/FiO2 ratio (P/F ratio) between groups|Incidence and severity of treatment-emergent adverse events|Change in C-reactive protein (CRP) levels|Proportional differences between groups on the Clinical Improvement Scale|Changes in P/F ratio|Changes in respiratory rate|Changes in oxygenation index|Changes in respiratory compliance (the change in lung volume per unit change in transmural pressure gradient)|Changes in positive end-expiratory pressure|Ventilator-free days|Proportional differences between groups on the SF-36|Proportional differences between groups on the mini mental state examination","Cynata Therapeutics Limited|Cerebral Palsy Alliance","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","24","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CYP-COVID-19-01","August 24, 2020","December 31, 2021","December 31, 2021","September 3, 2020",,"May 20, 2021","Nepean Hospital, Kingswood, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Footscray Hospital, Footscray, Victoria, Australia|Sunshine Hospital, Saint Albans, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT04537351"
41,"NCT03898817","Pathology of Helicases and Premature Aging: Study by Derivation of hiPS","HeliPS","Completed","No Results Available","Age Problem","Other: taking of cutaneous cells","Genomic instability : analysis|Genomic instability : size of telomers|Genomic instability : Duplication of centrosomes|cellular ageing : molecular analysis of hiPS cell derived from pathological tissue|cellular ageing : IPS line with the criteria defined for morphological characterization|cellular ageing : molecular characterization","University Hospital, Montpellier","All","18 Years to 65 Years   (Adult, Older Adult)",,"3","Other","Observational","Observational Model: Other|Time Perspective: Prospective","9360","September 2015","September 2017","March 2019","April 2, 2019",,"May 1, 2019","University Hospital Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT03898817"
42,"NCT03506061","Trikafta in Cystic Fibrosis Patients",,"Recruiting","No Results Available","Cystic Fibrosis","Drug: Trikafta","Change in forced expiratory volume in one second (FEV1)|Response of iPS cells to treatment|Change in sweat chloride|Change in nasal potential difference (NPD) measurements|Change in Cystic Fibrosis Questionnaire - Revised (CFQ-R) Score","Emory University|National Heart, Lung, and Blood Institute (NHLBI)","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","22","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00108656|300001205|R01HL139876","September 4, 2019","May 2023","May 2023","April 23, 2018",,"June 10, 2021","University of Alabama Cystic Fibrosis Research Center, Birmingham, Alabama, United States|Emory Children's Center, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT03506061"
43,"NCT02923375","A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease",,"Completed","No Results Available","Graft vs Host Disease","Biological: Mesenchymoangioblast-derived mesenchymal stem cells","Incidence and severity of treatment emergent adverse events [safety and tolerability]|Incidence and severity of serious adverse events deemed possibly related to CYP-001 [safety and tolerability]|Complete Response by Day 28|Partial Response by Day 28|Overall Survival at Day 28|Complete Response by Day 100|Partial Response by Day 100|Overall Survival at Day 100","Cynata Therapeutics Limited","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CYP-GvHD-P1-01|2016-000070-38","March 1, 2017","August 28, 2018","June 30, 2020","October 4, 2016",,"August 11, 2020","Sydney Local Health District, Sydney, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|NHS Foundation Trust, Bristol, United Kingdom|NHS Trust, Leeds, United Kingdom|NHS Foundation Trust, Liverpool, United Kingdom|NHS Foundation Trust, Manchester, United Kingdom|NHS Foundation Trust, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02923375"
44,"NCT02413450","Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias",,"Enrolling by invitation","No Results Available","Inherited Cardiac Arrythmias|Long QT Syndrome (LQTS)|Brugada Syndrome (BrS)|Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)|Early Repolarization Syndrome (ERS)|Arrhythmogenic Cardiomyopathy (AC, ARVD/C)|Hypertrophic Cardiomyopathy (HCM)|Dilated Cardiomyopathy (DCM)|Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)|Normal Control Subjects",,"•Production of cardiomyocytes and engineered tissues from hiPSC-derived cardiomyocytes to be used in mechanistic studies of disease and testing of therapeutic interventions.","Johns Hopkins University|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years to 85 Years   (Adult, Older Adult)",,"100","Other|NIH","Observational","Observational Model: Family-Based|Time Perspective: Prospective","NA_00085175|1R01HL128743-01A1","August 2013","August 2024","August 2024","April 10, 2015",,"January 11, 2021","Johns Hopkins Medical Institute, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT02413450"
45,"NCT03185702","UTHealth Turner Syndrome Research Registry",,"Recruiting","No Results Available","Turner Syndrome","Genetic: Research genetic tests","Bicuspid aortic valve and thoracic aortic aneurysm|Health-related quality of life","The University of Texas Health Science Center, Houston|American Heart Association","Female","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HSC-MS-15-0120","August 28, 2015","January 1, 2025","January 1, 2030","June 14, 2017",,"November 6, 2020","University of Texas Health Science Center Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03185702"
46,"NCT02574390","Answer ALS: Individualized Initiative for ALS Discovery","AnswerALS","Completed","No Results Available","Amyotrophic Lateral Sclerosis|Primary Lateral Sclerosis|Flail Arm ALS|Progressive Muscular Atrophy|Monomelic Amyotrophy|Motor Neuron Disease|Asymptomatic ALS Gene Carriers|Healthy Controls",,"ALS Functional Rating Scale-Revised (ALSFRS-R)|ALS Cognitive Behavioral Scale (ALS-CBS)|Slow Vital Capacity (SVC)|Strength Testing with Hand Held Dynamometer (HHD)","Johns Hopkins University|Massachusetts General Hospital|Emory University|Ohio State University|Washington University School of Medicine|Cedars-Sinai Medical Center|University of California, Irvine|Massachusetts Institute of Technology|New York Genome Center|Leandro P. Rizzuto Foundation|Texas Neurology|Northwestern University Les Turner ALS Center","All","18 Years to 100 Years   (Adult, Older Adult)",,"1049","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IRB00082277","December 2015","December 31, 2019","January 1, 2020","October 12, 2015",,"January 13, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States|Emory University, Atlanta, Georgia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Texas Neurology, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02574390"
47,"NCT03635294","Multi-Omics and IPSCs to Improve Diagnosis of Rare Intellectual Disabilities","MIDRID","Recruiting","No Results Available","Rare Intellectual Disabilities","Other: Blood sample","To evaluate the relevance and effectiveness of a multi-omics approach to the diagnosis of ID of unknown genetic origin.|The assessment of metabolomics consequences of CAMK2a mutations in human neuronal progenitors and differentiated neuronal cell lines|The assessment of morphological consequences of CAMK2a mutations in human neuronal progenitors and differentiated neuronal cell lines","University Hospital, Angers","All","2 Years to 25 Years   (Child, Adult)","Not Applicable","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","49RC17_0224","January 9, 2019","March 2020","March 2020","August 17, 2018",,"January 3, 2020","CHU Angers, Angers, France|HCL Lyon, Bron, France|CHU de Bourgogne, Dijon, France|CHU Nantes, Nantes, France|CHU Poitiers, Poitiers, France|CHU Rennes, Rennes, France",,"https://ClinicalTrials.gov/show/NCT03635294"
48,"NCT03434808","Generation of an Induced Pluripotent Stem (iPS) Cell Bank Immune Matched to a Majority of the US Population",,"Terminated","No Results Available","iPS Cell Manufacture and Banking","Other: Whole Blood Donation","Twelve whole blood samples donated for the manufacture and banking of iPS cells","Center for International Blood and Marrow Transplant Research|Cellular Dynamics International, Inc. - A FUJIFILM Company","All","18 Years to 61 Years   (Adult)","Not Applicable","19","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","15-CDI","January 13, 2017","August 17, 2018","August 17, 2018","February 15, 2018",,"July 15, 2020",,,"https://ClinicalTrials.gov/show/NCT03434808"
49,"NCT02450240","Latent Structure of Multi-level Assessments and Predictors of Outcomes in Psychiatric Disorders",,"Completed","No Results Available","Depression|Anxiety|Eating Disorders|Drug Use Disorders","Behavioral: standardized diagnostic assessment|Behavioral: self-report questionnaires|Behavioral: behavioral tasks|Other: physiological measurements|Other: structural and functional magnetic resonance imaging and EEG|Other: biomarker and microbiome assessments|Other: blood to derive induced pluripotent stem cells|Other: genetic and epigenetic assessments","Change from Baseline in Clinical Diagnosis","Laureate Institute for Brain Research, Inc.|University of Oklahoma|Rutgers University|University of California, San Diego","All","18 Years to 55 Years   (Adult)",,"1271","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2014-002","January 2015","June 2020","June 2020","May 21, 2015",,"July 7, 2020","Laureate Institute for Brain Research, Tulsa, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT02450240"
50,"NCT02926963","Generation of Powerful Biological Tools for Understanding the Pathophysiology of Chronic Granulomatous Disease.","FIBRO CGD","Terminated","No Results Available","Chronic Granulomatous Disease","Other: samples collection : hair and skin biopsy","to study the impact of protein deficits Nox2 and p22phox, in the physiopathology of neurons from inducible pluripotent bone marrow cells (iPSC)|To study the impact of protein deficits Nox2 and p22phox on cytochrome b558 synthesis process of phagocytes from inducible pluripotent bone marrow cells ( iPSC ).|To study the impact of protein deficits Nox2 and p22phox , at the physiology of fibroblasts and their transformation into myofibroblasts|Constitute cellular models of different types of CGD for future physiopathological studies and therapeutic trials","University Hospital, Grenoble","All","6 Months and older   (Child, Adult, Older Adult)","Not Applicable","3","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","38RC09.018|2009-A00944-53","October 2010","June 2017","June 2017","October 6, 2016",,"September 29, 2017","University Hospital, Grenoble Alpes, Grenoble, Cs10217, France",,"https://ClinicalTrials.gov/show/NCT02926963"
51,"NCT04674501","Radiotherapy for Thoracic and Breast Cancer and the Related Cardiotoxicity Following Treatment (RACCOON)",,"Recruiting","No Results Available","Patients Who Receive Thoracic Irradiation","Procedure: Cardiac evaluation and blood sampling","Cardiotoxicity rate|Overall survival|Cancer-specific survival|Progression-free survival|Other toxicity rates","Yonsei University","All","20 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","4-2020-1093","December 22, 2020","December 2022","December 2022","December 19, 2020",,"December 24, 2020","Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04674501"
52,"NCT00953693","Patient Specific Induced Pluripotency Stem Cells (PSiPS)",,"Completed","No Results Available","Hepatic Disorders|Eye Disorders","Procedure: Biopsy",,"Royan Institute","All","12 Years to 80 Years   (Child, Adult, Older Adult)",,"15","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Royan-iPS-001","April 2009","January 2010","July 2010","August 6, 2009",,"December 27, 2012","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT00953693"
53,"NCT03750734","Target Validation and Discovery in Idiopathic Bronchiectasis",,"Recruiting","No Results Available","Bronchiectasis|Idiopathic Bronchiectasis","Diagnostic Test: Bronchoscopy|Diagnostic Test: Blood test","Identification and comparison of molecular pathways, including through gene expression analysis of airway tissues.|Generation of air liquid interface cultures from primary bronchial epithelial cells/IPSC derived bronchial epithelial cells|Functional characterisation of airway epithelium","Papworth Hospital NHS Foundation Trust|GlaxoSmithKline","All","18 Years to 80 Years   (Adult, Older Adult)",,"50","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P02437","September 10, 2019","January 2022","January 2022","November 23, 2018",,"August 12, 2020","Royal Papworth Hospital, Cambridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03750734"
54,"NCT04982081","Treating Congestive HF With hiPSC-CMs Through Endocardial Injection",,"Recruiting","No Results Available","Cardiovascular Diseases|Congestive Heart Failure|Dilated Cardiomyopathy","Biological: hiPSC-CM therapy","Incidence of major serious adverse events (SAEs)|Incidence of severe arrhythmia|Incidence of newly formed tumors|Changes in penal reactive antibodies (PRA)|Changes in donor specific antibodies (DSA)|Overall Left Ventricular systolic performance as assessed by MRI|Overall Left Ventricular systolic performance as assessed by PET/ECT Scan|Functional status by 6 minute walk test|Functional status by New York Heart Association (NYHA) Classification|Minnesota Living With Heart Failure Questionnaire (MLHFQ)","Help Therapeutics|Xijing Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","20","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","LTao","August 1, 2021","December 30, 2022","July 31, 2023","July 29, 2021",,"July 29, 2021","Help Therapeutics, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT04982081"
55,"NCT03403699","Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy","iPSC","Recruiting","No Results Available","Diabetes Complications|Diabetic Retinopathy","Biological: Generation of inducible pluripotent stem cells","Generating iPSCs from peripheral blood|Differentiate iPSCs into CD34+ cells and mesoderm","University of Alabama at Birmingham","All","21 Years to 98 Years   (Adult, Older Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Other","300000173","January 11, 2018","January 31, 2022","January 31, 2022","January 19, 2018",,"August 16, 2021","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT03403699"
56,"NCT03682458","Study of Neurodegenerative Diseases Induced Stem Cells in Patients and Healthy Family Controls.","NeuronsiPS","Not yet recruiting","No Results Available","Neurodegenerative Diseases","Genetic: Study of Neurodegenerative Diseases Induced Stem Cells","Study of Neurodegenerative Diseases Induced Stem Cells (iPS) in Patients and Healthy Family Controls.","Neuromed IRCCS|San Raffaele University Hospital, Italy","All","Child, Adult, Older Adult",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CGM-02","October 1, 2019","October 1, 2020","October 1, 2022","September 24, 2018",,"March 13, 2019","Stefano Gambardella, Pozzilli, Isernia, Italy",,"https://ClinicalTrials.gov/show/NCT03682458"
57,"NCT02469207","Regenerative Cellular Therapies, Physiology, Pathology and Developmental Biology","RCT","Unknown status","No Results Available","Graft Rejection|Transplantation|Diabetes Mellitus","Other: Removal of tissue post-mortem","Number of donors from which induced Pluripotent Stem Cells were generated|Number of stem cell lines for which the immune response was characterised|Number of immunomodulatory therapies characterised|Levels of baseline and stimulated gut hormones detected","Cambridge University Hospitals NHS Foundation Trust|University of Cambridge|Cambridge Stem Cell Institute, Cambridge|Anne McLarent Laboratory of Regenerative Medicine, Cambridge|The Gurdon Institute, Cambridge|Sanger Institure, Cambridge|Institute of Metabolic Science, Cambridge|MRC Mitochondrial Biology Unit, Cambridge","All","16 Years to 92 Years   (Child, Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","A093532|15/EE/0152","January 2016","June 2020","June 2020","June 11, 2015",,"July 14, 2016","Addenbrooke's Hospital, Cambridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02469207"
58,"NCT03253705","Samples From Human Subjects to Facilitate Basic, Translational and Clinical Research",,"Enrolling by invitation","No Results Available","Endothelial Dysfunction|Inflammation in Cardiopulmonary and Vascular Disease States|Healthy Volunteers",,"Exploratory assay development","National Institutes of Health Clinical Center (CC)","All","18 Years to 100 Years   (Adult, Older Adult)",,"1000","NIH","Observational","Observational Model: Other|Time Perspective: Other","170148|17-CC-0148","September 14, 2017","August 1, 2027","August 1, 2027","August 18, 2017",,"July 14, 2021","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT03253705"
59,"NCT03025763","Network Of Clinical Research Studies On Craniosynostosis, Skull Malformations With Premature Fusion Of Skull Bones",,"Recruiting","No Results Available","Craniosynostosis","Other: Craniosynostosis Network Environmental Survey|Other: 2D/3D Photography|Procedure: Buccal Swab Cell Sampling|Procedure: Blood sampling|Procedure: Skin Biopsy|Procedure: Tissues from a Clinically Indicated Procedure|Procedure: Pre-operative CT Scan Image Files.","Phenotype-genotype gene expression correlations|Incidence of gene mutations","Icahn School of Medicine at Mount Sinai|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 80 Years   (Child, Adult, Older Adult)",,"4000","Other|NIH","Observational","Observational Model: Other|Time Perspective: Other","GCO 13-0147|P01HD078233","November 25, 2014","January 31, 2022","January 31, 2022","January 20, 2017",,"February 2, 2021","The International Craniosynostosis Consortium at University of California at Davis, Davis, California, United States|Yale University, Hartford, Connecticut, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|National Birth Defects Prevention Study at University of Iowa, Iowa City, Iowa, United States|Johns Hopkins University, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Birth Defect Registries of New York State, Albany, New York, United States|New York University, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Pennsylvania State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Pennsylvania State University, University Park, Pennsylvania, United States|Seton Family of Hospitals, Austin, Texas, United States|Medical City Children's Hospital, Dallas, Texas, United States|University of Texas at Southwestern, Dallas, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Bordeaux, Talence, Aquitaine, France|INSERM/ Hospital Necker-Enfants Malades, Paris, Cedex 14, France|University Hospital Heidelberg, Heidelberg, Germany|Hospital Sant Joan de Deu, Barcelona, Esplugues De Llobregat, Spain|Oxford University, Oxford, Oxfordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03025763"
60,"NCT01865981","Investigating Hereditary Cardiac Disease by Reprogramming Skin Cells to Heart Muscle","CLUE","Completed","No Results Available","Eletrophysiology of iPS-derived Cardiomyocytes",,"Derivation of iPS cells|Differentiation of iPS cells to cardiomyocytes|Electrophysiology on iPS-derived cardiomyocytes","University of Dundee","All","18 Years and older   (Adult, Older Adult)",,"2","Other","Observational","Observational Model: Other|Time Perspective: Other","2012CA04|T13/21","June 2013","June 1, 2017","June 1, 2017","May 31, 2013",,"July 7, 2020","University of Dundee, Dundee, Angus, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01865981"
61,"NCT02084407","Induction of Pluripotent Stem Cells From Human Fibroblasts of DM1 Patients",,"Completed","No Results Available","DM1","Other: Clinical examination, skin biopsy, blood and urine sampling","Measure of DM1 alterations in human cardiomyocytes derived from induced pluripotent stem cells|Molecular changes in human DM1 cardiomyocytes expressing pathogenic CUGexp-RNA","Institut de Myologie, France","All","20 Years to 50 Years   (Adult)","Not Applicable","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","DM1-Fibroblasts","November 2013","August 2014","August 2014","March 12, 2014",,"September 26, 2014","Institute of Myology, Paris, France",,"https://ClinicalTrials.gov/show/NCT02084407"
62,"NCT03372746","Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration",,"Completed","No Results Available","AMD",,"The primary outcome is to develop a repository for iPS cells for investigators involved in vision research.|Secondary outcomes include the assessment of potential therapies for the treatment of age related macular disorder (AMD).","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","50 Years and older   (Adult, Older Adult)",,"187","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","180027|18-EI-0027","May 23, 2018","March 21, 2019","March 21, 2019","December 14, 2017",,"April 5, 2019","Retina-Vitreous Associates Med Group, Beverly Hills, California, United States|Bascom Palmer Eye Institute, Miami, Florida, United States|Emory University Eye Center, Atlanta, Georgia, United States|Retina Vitreous Associates of Kentucky, Lexington, Kentucky, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|Elman Retina Group, P.A., Rosedale, Maryland, United States|Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States|Vision Research ROPARD Foundation/Associated Retinal Consultants, Grand Rapids, Grand Rapids, Michigan, United States|Vision Research ROPARD Foundation/Associated Retinal Consultants, Novi, Novi, Michigan, United States|Charlotte Eye Ear Nose &amp; Throat Associates, Charlotte, North Carolina, United States|Casey Eye Institute, Portland, Oregon, United States|Texas Retina Associates, Dallas, Texas, United States|John Moran Eye Center, University of Utah, Salt Lake City, Utah, United States|University of Wisconsin-Madison, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03372746"
63,"NCT01143454","Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System",,"Recruiting","No Results Available","Cardiomyopathy|Li-Fraumeni Syndrome|Parkinson's Disease|Atherosclerosis|Cardiovascular Capacity",,"Disease Diagnosis|Understanding disease pathophysiolgy|Potential genetic counseling","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","1 Year to 100 Years   (Child, Adult, Older Adult)",,"5000","NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","100126|10-H-0126","July 21, 2010",,,"June 14, 2010",,"November 8, 2021","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01143454"
64,"NCT01092208","Studies of Autistic Patients: Gene Networks and Clinical Subtypes",,"Terminated","No Results Available","Autism|Tuberous Sclerosis",,,"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Male","4 Years to 18 Years   (Child, Adult)",,"11","NIH","Observational","Time Perspective: Retrospective","100084|10-CH-0084","March 17, 2010",,"September 24, 2013","March 24, 2010",,"December 17, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01092208"
65,"NCT01432847","Cell Collection to Study Eye Diseases",,"Recruiting","No Results Available","Retinal Disease|AMD|Retinal Degeneration|Retinitis Pigmentosa",,"Creation of iPS cells from at least 1 type of somatic tissue collected from participants, differentiation of iPS cells into RPE and/or neural retinal The creation of iPS cells from at least one type of somatic tissue collected from participants.","National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC)","All","1 Year and older   (Child, Adult, Older Adult)",,"930","NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","110245|11-EI-0245","September 7, 2011",,,"September 13, 2011",,"October 26, 2021","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01432847"
66,"NCT03322306","Establishment of Genetic Basis for Neurological Disease by Genetic Screening",,"Enrolling by invitation","No Results Available","Neuro-Degenerative Disease","Genetic: Genechip screening kit","Specific genetic mutation","Chinese University of Hong Kong","All","18 Years to 80 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","iPS gene study CRE-2012.361","November 16, 2012","December 31, 2025","December 31, 2025","October 26, 2017",,"October 1, 2021","Prince of Wales Hospital, Hong Kong, Shatin, Hong Kong",,"https://ClinicalTrials.gov/show/NCT03322306"
